S&P 500

5.487,03

0,25%

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Avidity Biosciences Inc (RNA)
Avidity Biosciences Inc (RNA) Notícias

RNA

Avidity Biosciences (RNA)

Avidity Biosciences Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:RNA

1 2 3 4 5 6 7 8 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
17/06/2024	17:05	PR Newswire (US)	Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares	NASDAQ:RNA	Avidity Biosciences Inc
14/06/2024	20:06	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RNA	Avidity Biosciences Inc
14/06/2024	18:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RNA	Avidity Biosciences Inc
14/06/2024	17:10	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:RNA	Avidity Biosciences Inc
14/06/2024	10:00	PR Newswire (US)	Avidity Biosciences to Participate in Upcoming Investor Conference	NASDAQ:RNA	Avidity Biosciences Inc
13/06/2024	21:00	PR Newswire (US)	Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock	NASDAQ:RNA	Avidity Biosciences Inc
13/06/2024	17:26	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:RNA	Avidity Biosciences Inc
12/06/2024	17:01	PR Newswire (US)	Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock	NASDAQ:RNA	Avidity Biosciences Inc
12/06/2024	08:00	PR Newswire (US)	Avidity Announces Unprecedented AOC 1020 Data from Phase 1/2 FORTITUDE™ Trial Demonstrating Greater Than 50 Percent Reduction in DUX4 Regulated Genes and Trends of Functional Improvement in People Living with Facioscapulohumeral Muscular Dystrophy	NASDAQ:RNA	Avidity Biosciences Inc
29/05/2024	17:05	PR Newswire (US)	Avidity Biosciences to Present Preliminary Data from Phase 1/2 FORTITUDE™ Trial of AOC 1020 in People Living with Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research Congress	NASDAQ:RNA	Avidity Biosciences Inc
21/05/2024	17:05	PR Newswire (US)	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:RNA	Avidity Biosciences Inc
16/05/2024	19:15	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:RNA	Avidity Biosciences Inc
15/05/2024	10:10	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:RNA	Avidity Biosciences Inc
15/05/2024	10:00	PR Newswire (US)	Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors	NASDAQ:RNA	Avidity Biosciences Inc
09/05/2024	17:22	Edgar (US Regulatory)	Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers	NASDAQ:RNA	Avidity Biosciences Inc
09/05/2024	17:13	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:RNA	Avidity Biosciences Inc
09/05/2024	17:05	PR Newswire (US)	Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights	NASDAQ:RNA	Avidity Biosciences Inc
08/05/2024	07:00	PR Newswire (US)	Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1	NASDAQ:RNA	Avidity Biosciences Inc
27/03/2024	10:00	PR Newswire (US)	Avidity Biosciences to Participate in Upcoming Investor Conferences	NASDAQ:RNA	Avidity Biosciences Inc
04/03/2024	09:00	PR Newswire (US)	Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial	NASDAQ:RNA	Avidity Biosciences Inc
29/02/2024	18:19	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:RNA	Avidity Biosciences Inc
29/02/2024	14:00	PR Newswire (US)	Avidity Biosciences Honors Rare Disease Day®	NASDAQ:RNA	Avidity Biosciences Inc
29/02/2024	09:00	PR Newswire (US)	Avidity Biosciences Announces Oversubscribed $400 Million Private Placement	NASDAQ:RNA	Avidity Biosciences Inc
28/02/2024	18:17	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:RNA	Avidity Biosciences Inc
28/02/2024	18:05	PR Newswire (US)	Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights	NASDAQ:RNA	Avidity Biosciences Inc
20/02/2024	11:00	PR Newswire (US)	Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping	NASDAQ:RNA	Avidity Biosciences Inc
15/02/2024	19:00	PR Newswire (US)	Avidity Biosciences to Present New AOC 1001 Long-term Efficacy and Safety Data from MARINA-OLE™ Trial in People Living with Myotonic Dystrophy Type 1 (DM1) at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference	NASDAQ:RNA	Avidity Biosciences Inc
02/02/2024	14:08	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:RNA	Avidity Biosciences Inc
05/01/2024	10:30	PR Newswire (US)	Avidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of Growth	NASDAQ:RNA	Avidity Biosciences Inc
13/12/2023	10:30	PR Newswire (US)	Avidity Biosciences Reports Positive Data Demonstrating AOC 1044 Delivers Unprecedented Concentrations of PMO in Muscle Following a Single Dose in Healthy Volunteers from Phase 1/2 EXPLORE44™ Trial for Duchenne Muscular Dystrophy	NASDAQ:RNA	Avidity Biosciences Inc